Nuochengjianhua announced today that the phase I clinical trial targeting TL1a and IL-23p19 novel bispecific antibody ICP-B161, which was independently developed by the company, has completed the enrollment of the first test subjects and is intended to treat autoimmune diseases such as inflammatory bowel disease.
智通財經·10/30/2026 02:34:03
語音播報
Nuochengjianhua announced today that the phase I clinical trial targeting TL1a and IL-23p19 novel bispecific antibody ICP-B161, which was independently developed by the company, has completed the enrollment of the first test subjects and is intended to treat autoimmune diseases such as inflammatory bowel disease.